Filing Details

Accession Number:
0000899243-20-035198
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-28 16:30:26
Reporting Period:
2020-12-22
Accepted Time:
2020-12-28 16:30:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1402479 Medavail Holdings Inc. MDVL Pharmaceutical Preparations (2834) 900772394
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1668029 Fan Yu Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
1766516 L.p. Management Medalpha Bridge Ally 430 Park Avenue, 12Th Floor,
New York NY 10022
No No Yes No
1808684 Ally Bridge Group-Wtt Global Life Science Capital Partners, L.p. Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
1822947 Ally Bridge Group (Ny) Llc 430 Park Avenue, 12Th Floor,
New York NY 10022
No No Yes No
1831963 L.p. Fund Master Medalpha Bridge Ally 430 Park Avenue, 12Th Floor,
New York NY 10022
No No Yes No
1832106 Ltd. Management Abg Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
1832107 Ally Bridge Medalpha Management Gp, Llc 430 Park Avenue, 12Th Floor,
New York NY 10022
No No Yes No
1832108 Ltd Gp Partners Capital Science Life Global Abg-Wtt Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
1832109 Abg-Wtt Global Life Science Capital Partners Gp, L.p. Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
1832110 Ltd Wtt-Medavail Abg Unit 3002-3004, 30Th Floor
Gloucester Tower, The Landmark, Central
Hong Kong K3
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-22 9,287 $13.70 3,858,298 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-12-22 7,661 $13.70 2,897,966 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-12-23 11,890 $13.99 3,870,188 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-12-23 9,810 $13.99 2,907,776 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-12-24 4,871 $13.99 3,875,059 No 4 P Indirect See Footnote
Common Stock Acquisiton 2020-12-24 4,019 $13.99 2,911,795 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.45 to $13.96. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
  3. These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.91 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.90 to $14.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.